BNP Paribas Financial Markets
CCCC icon

BNP Paribas Financial Markets’s C4 Therapeutics CCCC Stock Holding History

BNP Paribas Financial Markets’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$501K Buy
190,348
+188,187
+8,708% +$443K ﹤0.01% 3589
2025
Q4 		$4.13K Sell
2,161
-78,645
-97% -$186K ﹤0.01% 5279
2025
Q3 		$179K Sell
80,806
-125,371
-61% -$301K ﹤0.01% 4055
2025
Q2 		$295K Buy
206,177
+188,081
+1,039% +$274K ﹤0.01% 3614
2025
Q1 		$29K Buy
18,096
+11,354
+168% +$33.9K ﹤0.01% 4441
2024
Q4 		$24.3K Buy
+6,742
New +$33.5K ﹤0.01% 4680

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BNP Paribas Financial Markets's CCCC Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its C4 Therapeutics (CCCC) stake by 8,708% in Q1 2026, buying an estimated $443K and bringing the position to 190,348 shares worth $501K. The position accounts for ﹤0.01% of the portfolio, ranked #3589.

BNP Paribas Financial Markets first reported a position in CCCC in Q4 2024 and has held it in 6 quarters since. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • BNP Paribas Financial Markets held 190,348 shares of C4 Therapeutics worth $501K as of Q1 2026.
  • BNP Paribas Financial Markets bought 188,187 C4 Therapeutics shares in Q1 2026, an estimated $443K.
  • C4 Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #3589 holding.
  • BNP Paribas Financial Markets first reported a position in C4 Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.